Symbols

ADMA

ADMA Biologics·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Beats Expectation

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ADMA

Adma Biologics, Inc.

A company that develops specialty plasma-based biologics for the treatment and prevention of infectious diseases

Industry

Pharmaceutical

Established Date

06/24/2004

Listing Date

11/10/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

647

Fiscal Year Ends

12-31

Website

www.admabiologics.com

Security Type

Common stock

Office address

465 State Route 17, Ramsey, New Jersey 07446

Business

Introduction

ADMA Biologics, Inc., was incorporated as a New Jersey corporation on June 24, 2004 and re-incorporated in Delaware on July 16, 2007. The Company is an end-to-end commercial biopharmaceutical company headquartered in the United States that manufactures, markets and develops specialty biological products for immunodeficient patients and populations at risk for specific infectious diseases. It sells three FDA-approved products — ASCENIV, BIVIGAM and Nabi-HB — which are manufactured at its Florida facility and operate an FDA-licensed plasma collection center.

Company Financials

EPS

ADMA has released its 2025 Q4 earnings. EPS was reported at 0.2, versus the expected 0.19, beating expectations. The chart below visualizes how ADMA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ADMA has released its 2025 Q4 earnings report, with revenue of 139.16M, reflecting a YoY change of 18.39%, and net profit of 49.38M, showing a YoY change of -55.87%. The Sankey diagram below clearly presents ADMA's revenue sources and cost distribution.